APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mirabegron Sustained-release Tablets

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Mirabegron Sustained-release Tablets Industry Growth and Trends Forecast to 2032

27 December 2025108 pages

Choose your research edition.

Industry ResearchMirabegron Sustained-release Tablets Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Mirabegron Sustained-release Tablets Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Mirabegron Sustained-release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mirabegron Sustained-release Tablets Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Mirabegron Sustained-release Tablets Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Mirabegron Sustained-release Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mirabegron Sustained-release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Mirabegron Sustained-release Tablets include Alkem Laboratories, Astellas Pharma, Lupin Pharmaceuticals, Zydus Lifesciences, China Resources Pharmaceutical, Jiangsu Huayang Pharmaceutical, Jiangxi Shanxiang Pharmaceutical, Qilu Pharmaceutical and Shenzhen Main Luck Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Mirabegron Sustained-release Tablets market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Mirabegron Sustained-release Tablets market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Mirabegron Sustained-release Tablets market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Mirabegron Sustained-release Tablets.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Mirabegron Sustained-release Tablets market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Mirabegron Sustained-release Tablets Market by Company

Alkem Laboratories

Astellas Pharma

Lupin Pharmaceuticals

Zydus Lifesciences

China Resources Pharmaceutical

Jiangsu Huayang Pharmaceutical

Jiangxi Shanxiang Pharmaceutical

Qilu Pharmaceutical

Shenzhen Main Luck Pharmaceuticals

CSPC Pharmaceutical

Sichuan Gowell Pharmaceutical

Zhejiang Huayi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Mirabegron Sustained-release Tablets Segment by Type

25mg per Tablet

50mg per Tablet

Mirabegron Sustained-release Tablets Segment by Application

Hospital and Clinic

Pharmacy

Other

Mirabegron Sustained-release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mirabegron Sustained-release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mirabegron Sustained-release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mirabegron Sustained-release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Mirabegron Sustained-release Tablets manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Mirabegron Sustained-release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 25mg per Tablet Table 2. Major Company of 50mg per Tablet Table 3. Global Mirabegron Sustained-release Tablets Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 5. Global Mirabegron Sustained-release Tablets Sales Market Share in Volume by Type (2021-2026) Table 6. Global Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (US$ Million) Table 7. Global Mirabegron Sustained-release Tablets Sales Market Share in Value by Type (2021-2026) Table 8. Global Mirabegron Sustained-release Tablets Price by Type (2021-2026) & (US$/Unit) Table 9. Global Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (K Units) Table 10. Global Mirabegron Sustained-release Tablets Sales Market Share in Volume by Type (2027-2032) Table 11. Global Mirabegron Sustained-release Tablets Sales by Type (2027-2032) & (US$ Million) Table 12. Global Mirabegron Sustained-release Tablets Sales Market Share in Value by Type (2027-2032) Table 13. Global Mirabegron Sustained-release Tablets Price by Type (2027-2032) & (US$/Unit) Table 14. North America Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 15. North America Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 17. Europe Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 21. Latin America Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Type (2021-2026) & (US$ Million) Table 24. Mirabegron Sustained-release Tablets Industry Trends Table 25. Mirabegron Sustained-release Tablets Industry Drivers Table 26. Mirabegron Sustained-release Tablets Industry Opportunities and Challenges Table 27. Mirabegron Sustained-release Tablets Industry Restraints Table 28. Global Mirabegron Sustained-release Tablets Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Mirabegron Sustained-release Tablets Revenue Market Share by Company (2021-2026) Table 30. Global Mirabegron Sustained-release Tablets Sales by Company (2021-2026) & (K Units) Table 31. Global Mirabegron Sustained-release Tablets Sales Share by Company (2021-2026) Table 32. Global Mirabegron Sustained-release Tablets Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Mirabegron Sustained-release Tablets Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Mirabegron Sustained-release Tablets Major Company Production Sites and Headquarters Table 35. Global Mirabegron Sustained-release Tablets Company, Product Type & Application Table 36. Global Mirabegron Sustained-release Tablets Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Mirabegron Sustained-release Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Mirabegron Sustained-release Tablets Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Mirabegron Sustained-release Tablets Sales by Region (2021-2026) & (K Units) Table 41. Global Mirabegron Sustained-release Tablets Sales Market Share in Volume by Region (2021-2026) Table 42. Global Mirabegron Sustained-release Tablets Sales by Region (2021-2026) & (US$ Million) Table 43. Global Mirabegron Sustained-release Tablets Sales Market Share in Value by Region (2021-2026) Table 44. Global Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Mirabegron Sustained-release Tablets Sales by Region (2027-2032) & (K Units) Table 46. Global Mirabegron Sustained-release Tablets Sales Market Share in Volume by Region (2027-2032) Table 47. Global Mirabegron Sustained-release Tablets Sales by Region (2027-2032) & (US$ Million) Table 48. Global Mirabegron Sustained-release Tablets Sales Market Share in Value by Region (2027-2032) Table 49. Global Mirabegron Sustained-release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Mirabegron Sustained-release Tablets Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 52. Global Mirabegron Sustained-release Tablets Sales Market Share in Volume by Application (2021-2026) Table 53. Global Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (US$ Million) Table 54. Global Mirabegron Sustained-release Tablets Sales Market Share in Value by Application (2021-2026) Table 55. Global Mirabegron Sustained-release Tablets Price by Application (2021-2026) & (US$/Unit) Table 56. Global Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (K Units) Table 57. Global Mirabegron Sustained-release Tablets Sales Market Share in Volume by Application (2027-2032) Table 58. Global Mirabegron Sustained-release Tablets Sales by Application (2027-2032) & (US$ Million) Table 59. Global Mirabegron Sustained-release Tablets Sales Market Share in Value by Application (2027-2032) Table 60. Global Mirabegron Sustained-release Tablets Price by Application (2027-2032) & (US$/Unit) Table 61. North America Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 62. North America Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 64. Europe Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 68. Latin America Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Application (2021-2026) & (US$ Million) Table 71. Alkem Laboratories Company Information Table 72. Alkem Laboratories Business Overview Table 73. Alkem Laboratories Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio Table 75. Alkem Laboratories Recent Development Table 76. Astellas Pharma Company Information Table 77. Astellas Pharma Business Overview Table 78. Astellas Pharma Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio Table 80. Astellas Pharma Recent Development Table 81. Lupin Pharmaceuticals Company Information Table 82. Lupin Pharmaceuticals Business Overview Table 83. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 85. Lupin Pharmaceuticals Recent Development Table 86. Zydus Lifesciences Company Information Table 87. Zydus Lifesciences Business Overview Table 88. Zydus Lifesciences Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio Table 90. Zydus Lifesciences Recent Development Table 91. China Resources Pharmaceutical Company Information Table 92. China Resources Pharmaceutical Business Overview Table 93. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 95. China Resources Pharmaceutical Recent Development Table 96. Jiangsu Huayang Pharmaceutical Company Information Table 97. Jiangsu Huayang Pharmaceutical Business Overview Table 98. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 100. Jiangsu Huayang Pharmaceutical Recent Development Table 101. Jiangxi Shanxiang Pharmaceutical Company Information Table 102. Jiangxi Shanxiang Pharmaceutical Business Overview Table 103. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 105. Jiangxi Shanxiang Pharmaceutical Recent Development Table 106. Qilu Pharmaceutical Company Information Table 107. Qilu Pharmaceutical Business Overview Table 108. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 110. Qilu Pharmaceutical Recent Development Table 111. Shenzhen Main Luck Pharmaceuticals Company Information Table 112. Shenzhen Main Luck Pharmaceuticals Business Overview Table 113. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio Table 115. Shenzhen Main Luck Pharmaceuticals Recent Development Table 116. CSPC Pharmaceutical Company Information Table 117. CSPC Pharmaceutical Business Overview Table 118. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 120. CSPC Pharmaceutical Recent Development Table 121. Sichuan Gowell Pharmaceutical Company Information Table 122. Sichuan Gowell Pharmaceutical Business Overview Table 123. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 125. Sichuan Gowell Pharmaceutical Recent Development Table 126. Zhejiang Huayi Pharmaceutical Company Information Table 127. Zhejiang Huayi Pharmaceutical Business Overview Table 128. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 130. Zhejiang Huayi Pharmaceutical Recent Development Table 131. Chia Tai Tianqing Pharmaceutical Company Information Table 132. Chia Tai Tianqing Pharmaceutical Business Overview Table 133. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio Table 135. Chia Tai Tianqing Pharmaceutical Recent Development Table 136. North America Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. North America Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 138. North America Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2026) Table 139. North America Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032) & (K Units) Table 140. North America Mirabegron Sustained-release Tablets Sales Market Share Forecast by Country (2027-2032) Table 141. North America Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. North America Mirabegron Sustained-release Tablets Market Size by Country (2021-2026) & (US$ Million) Table 143. North America Mirabegron Sustained-release Tablets Market Share by Country (2021-2026) Table 144. North America Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. North America Mirabegron Sustained-release Tablets Market Share Forecast by Country (2027-2032) Table 146. Europe Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 148. Europe Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2026) Table 149. Europe Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032) & (K Units) Table 150. Europe Mirabegron Sustained-release Tablets Sales Market Share Forecast by Country (2027-2032) Table 151. Europe Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Europe Mirabegron Sustained-release Tablets Market Size by Country (2021-2026) & (US$ Million) Table 153. Europe Mirabegron Sustained-release Tablets Market Share by Country (2021-2026) Table 154. Europe Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Europe Mirabegron Sustained-release Tablets Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 158. Asia-Pacific Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2026) Table 159. Asia-Pacific Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032) & (K Units) Table 160. Asia-Pacific Mirabegron Sustained-release Tablets Sales Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Mirabegron Sustained-release Tablets Market Size by Country (2021-2026) & (US$ Million) Table 163. Asia-Pacific Mirabegron Sustained-release Tablets Market Share by Country (2021-2026) Table 164. Asia-Pacific Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Asia-Pacific Mirabegron Sustained-release Tablets Market Share Forecast by Country (2027-2032) Table 166. Latin America Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 167. Latin America Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 168. Latin America Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2026) Table 169. Latin America Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032) & (K Units) Table 170. Latin America Mirabegron Sustained-release Tablets Sales Market Share Forecast by Country (2027-2032) Table 171. Latin America Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Latin America Mirabegron Sustained-release Tablets Market Size by Country (2021-2026) & (US$ Million) Table 173. Latin America Mirabegron Sustained-release Tablets Market Share by Country (2021-2026) Table 174. Latin America Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Latin America Mirabegron Sustained-release Tablets Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2026) & (K Units) Table 178. Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share by Country (2021-2026) Table 179. Middle East and Africa Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032) & (K Units) Table 180. Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Mirabegron Sustained-release Tablets Market Size by Country (2021-2026) & (US$ Million) Table 183. Middle East and Africa Mirabegron Sustained-release Tablets Market Share by Country (2021-2026) Table 184. Middle East and Africa Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Middle East and Africa Mirabegron Sustained-release Tablets Market Share Forecast by Country (2027-2032) Table 186. Key Raw Materials Table 187. Raw Materials Key Suppliers Table 188. Mirabegron Sustained-release Tablets Distributors List Table 189. Mirabegron Sustained-release Tablets Customers List Table 190. Research Programs/Design for This Report Table 191. Authors List of This Report Table 192. Secondary Sources Table 193. Primary Sources List of Figures Figure 1. Mirabegron Sustained-release Tablets Image Figure 2. Global Mirabegron Sustained-release Tablets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mirabegron Sustained-release Tablets Market Size (2021-2032) & (US$ Million) Figure 4. Global Mirabegron Sustained-release Tablets Sales (2021-2032) & (K Units) Figure 5. 25mg per Tablet Image Figure 6. Global 25mg per Tablet Sales YoY Growth (2021-2032) & (K Units) Figure 7. 50mg per Tablet Image Figure 8. Global 50mg per Tablet Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Mirabegron Sustained-release Tablets Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Mirabegron Sustained-release Tablets Market Share by Type 2025 VS 2032 Figure 11. North America Mirabegron Sustained-release Tablets Sales Market Share in Volume by Type in 2025 Figure 12. North America Mirabegron Sustained-release Tablets Sales Market Share in Value by Type in 2025 Figure 13. Europe Mirabegron Sustained-release Tablets Sales Market Share in Volume by Type in 2025 Figure 14. Europe Mirabegron Sustained-release Tablets Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Mirabegron Sustained-release Tablets Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Mirabegron Sustained-release Tablets Sales Market Share in Value by Type in 2025 Figure 17. Latin America Mirabegron Sustained-release Tablets Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Mirabegron Sustained-release Tablets Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Mirabegron Sustained-release Tablets Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital and Clinic Image Figure 24. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 25. Pharmacy Image Figure 26. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Mirabegron Sustained-release Tablets Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Mirabegron Sustained-release Tablets Market Share by Application 2025 VS 2032 Figure 31. North America Mirabegron Sustained-release Tablets Sales Market Share in Volume by Application in 2025 Figure 32. North America Mirabegron Sustained-release Tablets Sales Market Share in Value by Application in 2025 Figure 33. Europe Mirabegron Sustained-release Tablets Sales Market Share in Volume by Application in 2025 Figure 34. Europe Mirabegron Sustained-release Tablets Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Mirabegron Sustained-release Tablets Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Mirabegron Sustained-release Tablets Sales Market Share in Value by Application in 2025 Figure 37. Latin America Mirabegron Sustained-release Tablets Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Mirabegron Sustained-release Tablets Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Mirabegron Sustained-release Tablets Sales Market Share in Value by Application in 2025 Figure 41. North America Mirabegron Sustained-release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Mirabegron Sustained-release Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Mirabegron Sustained-release Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Mirabegron Sustained-release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Mirabegron Sustained-release Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Mirabegron Sustained-release Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Mirabegron Sustained-release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Mirabegron Sustained-release Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Mirabegron Sustained-release Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Mirabegron Sustained-release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Mirabegron Sustained-release Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Mirabegron Sustained-release Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Mirabegron Sustained-release Tablets Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Mirabegron Sustained-release Tablets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Mirabegron Sustained-release Tablets Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Mirabegron Sustained-release Tablets Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Mirabegron Sustained-release Tablets Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • 25mg per Tablet
  • 50mg per Tablet
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Alkem Laboratories
  • Astellas Pharma
  • Lupin Pharmaceuticals
  • Zydus Lifesciences
  • China Resources Pharmaceutical
  • Jiangsu Huayang Pharmaceutical
  • Jiangxi Shanxiang Pharmaceutical
  • Qilu Pharmaceutical
  • Shenzhen Main Luck Pharmaceuticals
  • CSPC Pharmaceutical
  • Sichuan Gowell Pharmaceutical
  • Zhejiang Huayi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Mirabegron Sustained-release Tablets Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Mirabegron Sustained-release Tablets Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Mirabegron Sustained-release Tablets Market by Type
  6. 1.3.1 25mg per Tablet
  7. 1.3.2 50mg per Tablet
  8. 1.4 Global Mirabegron Sustained-release Tablets Market Size by Type
  9. 1.4.1 Global Mirabegron Sustained-release Tablets Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Mirabegron Sustained-release Tablets Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Mirabegron Sustained-release Tablets Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Mirabegron Sustained-release Tablets Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Mirabegron Sustained-release Tablets Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Mirabegron Sustained-release Tablets Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Mirabegron Sustained-release Tablets Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Mirabegron Sustained-release Tablets Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Mirabegron Sustained-release Tablets Industry Trends
  2. 2.2 Mirabegron Sustained-release Tablets Industry Drivers
  3. 2.3 Mirabegron Sustained-release Tablets Industry Opportunities and Challenges
  4. 2.4 Mirabegron Sustained-release Tablets Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Mirabegron Sustained-release Tablets Revenue (2021-2026)
  2. 3.2 Global Top Players by Mirabegron Sustained-release Tablets Sales (2021-2026)
  3. 3.3 Global Top Players by Mirabegron Sustained-release Tablets Price (2021-2026)
  4. 3.4 Global Mirabegron Sustained-release Tablets Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Mirabegron Sustained-release Tablets Major Company Production Sites & Headquarters
  6. 3.6 Global Mirabegron Sustained-release Tablets Company, Product Type & Application
  7. 3.7 Global Mirabegron Sustained-release Tablets Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Mirabegron Sustained-release Tablets Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Mirabegron Sustained-release Tablets Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Mirabegron Sustained-release Tablets Tier 1, Tier 2, and Tier 3
4 Mirabegron Sustained-release Tablets Regional Status and Outlook
  1. 4.1 Global Mirabegron Sustained-release Tablets Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Mirabegron Sustained-release Tablets Historic Market Size by Region
  3. 4.2.1 Global Mirabegron Sustained-release Tablets Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Mirabegron Sustained-release Tablets Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Mirabegron Sustained-release Tablets Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Mirabegron Sustained-release Tablets Forecasted Market Size by Region
  7. 4.3.1 Global Mirabegron Sustained-release Tablets Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Mirabegron Sustained-release Tablets Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Mirabegron Sustained-release Tablets Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Mirabegron Sustained-release Tablets by Application
  1. 5.1 Mirabegron Sustained-release Tablets Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Mirabegron Sustained-release Tablets Market Size by Application
  6. 5.2.1 Global Mirabegron Sustained-release Tablets Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Mirabegron Sustained-release Tablets Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Mirabegron Sustained-release Tablets Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Mirabegron Sustained-release Tablets Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Mirabegron Sustained-release Tablets Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Mirabegron Sustained-release Tablets Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Mirabegron Sustained-release Tablets Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Mirabegron Sustained-release Tablets Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Alkem Laboratories
  2. 6.1.1 Alkem Laboratories Company Information
  3. 6.1.2 Alkem Laboratories Business Overview
  4. 6.1.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolio
  6. 6.1.5 Alkem Laboratories Recent Developments
  7. 6.2 Astellas Pharma
  8. 6.2.1 Astellas Pharma Company Information
  9. 6.2.2 Astellas Pharma Business Overview
  10. 6.2.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolio
  12. 6.2.5 Astellas Pharma Recent Developments
  13. 6.3 Lupin Pharmaceuticals
  14. 6.3.1 Lupin Pharmaceuticals Company Information
  15. 6.3.2 Lupin Pharmaceuticals Business Overview
  16. 6.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  18. 6.3.5 Lupin Pharmaceuticals Recent Developments
  19. 6.4 Zydus Lifesciences
  20. 6.4.1 Zydus Lifesciences Company Information
  21. 6.4.2 Zydus Lifesciences Business Overview
  22. 6.4.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolio
  24. 6.4.5 Zydus Lifesciences Recent Developments
  25. 6.5 China Resources Pharmaceutical
  26. 6.5.1 China Resources Pharmaceutical Company Information
  27. 6.5.2 China Resources Pharmaceutical Business Overview
  28. 6.5.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  30. 6.5.5 China Resources Pharmaceutical Recent Developments
  31. 6.6 Jiangsu Huayang Pharmaceutical
  32. 6.6.1 Jiangsu Huayang Pharmaceutical Company Information
  33. 6.6.2 Jiangsu Huayang Pharmaceutical Business Overview
  34. 6.6.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  36. 6.6.5 Jiangsu Huayang Pharmaceutical Recent Developments
  37. 6.7 Jiangxi Shanxiang Pharmaceutical
  38. 6.7.1 Jiangxi Shanxiang Pharmaceutical Company Information
  39. 6.7.2 Jiangxi Shanxiang Pharmaceutical Business Overview
  40. 6.7.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  42. 6.7.5 Jiangxi Shanxiang Pharmaceutical Recent Developments
  43. 6.8 Qilu Pharmaceutical
  44. 6.8.1 Qilu Pharmaceutical Company Information
  45. 6.8.2 Qilu Pharmaceutical Business Overview
  46. 6.8.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  48. 6.8.5 Qilu Pharmaceutical Recent Developments
  49. 6.9 Shenzhen Main Luck Pharmaceuticals
  50. 6.9.1 Shenzhen Main Luck Pharmaceuticals Company Information
  51. 6.9.2 Shenzhen Main Luck Pharmaceuticals Business Overview
  52. 6.9.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolio
  54. 6.9.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
  55. 6.10 CSPC Pharmaceutical
  56. 6.10.1 CSPC Pharmaceutical Company Information
  57. 6.10.2 CSPC Pharmaceutical Business Overview
  58. 6.10.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  60. 6.10.5 CSPC Pharmaceutical Recent Developments
  61. 6.11 Sichuan Gowell Pharmaceutical
  62. 6.11.1 Sichuan Gowell Pharmaceutical Company Information
  63. 6.11.2 Sichuan Gowell Pharmaceutical Business Overview
  64. 6.11.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  66. 6.11.5 Sichuan Gowell Pharmaceutical Recent Developments
  67. 6.12 Zhejiang Huayi Pharmaceutical
  68. 6.12.1 Zhejiang Huayi Pharmaceutical Company Information
  69. 6.12.2 Zhejiang Huayi Pharmaceutical Business Overview
  70. 6.12.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  72. 6.12.5 Zhejiang Huayi Pharmaceutical Recent Developments
  73. 6.13 Chia Tai Tianqing Pharmaceutical
  74. 6.13.1 Chia Tai Tianqing Pharmaceutical Company Information
  75. 6.13.2 Chia Tai Tianqing Pharmaceutical Business Overview
  76. 6.13.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolio
  78. 6.13.5 Chia Tai Tianqing Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Mirabegron Sustained-release Tablets Sales by Country
  2. 7.1.1 North America Mirabegron Sustained-release Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
  4. 7.1.3 North America Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032)
  5. 7.2 North America Mirabegron Sustained-release Tablets Market Size by Country
  6. 7.2.1 North America Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Mirabegron Sustained-release Tablets Market Size by Country (2021-2026)
  8. 7.2.3 North America Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Mirabegron Sustained-release Tablets Sales by Country
  2. 8.1.1 Europe Mirabegron Sustained-release Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
  4. 8.1.3 Europe Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Mirabegron Sustained-release Tablets Market Size by Country
  6. 8.2.1 Europe Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Mirabegron Sustained-release Tablets Market Size by Country (2021-2026)
  8. 8.2.3 Europe Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Mirabegron Sustained-release Tablets Sales by Country
  2. 9.1.1 Asia-Pacific Mirabegron Sustained-release Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Mirabegron Sustained-release Tablets Market Size by Country
  6. 9.2.1 Asia-Pacific Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Mirabegron Sustained-release Tablets Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Mirabegron Sustained-release Tablets Sales by Country
  2. 10.1.1 South America Mirabegron Sustained-release Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
  4. 10.1.3 South America Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032)
  5. 10.2 South America Mirabegron Sustained-release Tablets Market Size by Country
  6. 10.2.1 South America Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Mirabegron Sustained-release Tablets Market Size by Country (2021-2026)
  8. 10.2.3 South America Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country
  2. 11.1.1 Middle East and Africa Mirabegron Sustained-release Tablets Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Mirabegron Sustained-release Tablets Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Mirabegron Sustained-release Tablets Market Size by Country
  6. 11.2.1 Middle East and Africa Mirabegron Sustained-release Tablets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Mirabegron Sustained-release Tablets Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Mirabegron Sustained-release Tablets Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Mirabegron Sustained-release Tablets Value Chain Analysis
  2. 12.1.1 Mirabegron Sustained-release Tablets Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Mirabegron Sustained-release Tablets Production Mode & Process
  7. 12.2 Mirabegron Sustained-release Tablets Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Mirabegron Sustained-release Tablets Distributors
  10. 12.2.3 Mirabegron Sustained-release Tablets Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst